Loading clinical trials...
Loading clinical trials...
Early Phase I Evaluation of 64Cu-LLP2A for Imaging Hematologic Malignancies Part B
This phase of the protocol (protocol part B), seeks to evaluate the new formulation in healthy normal volunteers to confirm the new formulation provides comparable human dosimetry to which was seen and published in protocol part A. Additionally, the new formulation will be studied utilizing an expanded patient population to include patients with confirmed diagnosis of multiple myeloma (MM), low-grade lymphoma, or MM and lymphoma patients who are status post bone marrow transplant (BMT) with negative imaging and suspected recurrence.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
Yes
Washington University School of Medicine
St Louis, Missouri, United States
Start Date
February 26, 2025
Primary Completion Date
March 31, 2027
Completion Date
March 31, 2027
Last Updated
July 31, 2025
42
ESTIMATED participants
64Cu-LLP2A
DRUG
PET/CT
DEVICE
Lead Sponsor
Washington University School of Medicine
Collaborators
NCT06152575
NCT06179888
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06337318